country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-19869

Copy Link Print Information

VRX-480773

VRX-480773 is an efficient non-nucleoside reverse transcriptase inhibitor (NNRTI), used for HIV infection. VRX-480773 has high specificity for HIV-1, with an EC₅₀ for wild-type HIV-1 being 0.14 nM. VRX-480773 does not inhibit HIV-2, HBV or HCV, and has no effect on human DNA polymerase α/β. VRX-480773 retains inhibitory activity against Efavirenz (HY-10572) resistant strains, with EC₅₀s mostly < 1 nM. VRX-480773 can be used for research on AIDS.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

CAS No.: 878670-89-4
화학식: C₂₃H₁₉BrClN₅O₃S₂
분자량:592.92

보관:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (270 KB)

VRX-480773 Chemical Structure

CAS No.: 878670-89-4

Amount: USD 0.00

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- 제품 설명
- IC₅₀ & Target
- Cellular Effect
Chemical Information
순도&문서
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

제품 설명

IC₅₀ & Target

^[1]

HIV-1 (WT)

0.14 nM (EC₅₀)

All HIV Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
HeLa	CC₅₀	>=3 μM Compound: 24; VRX-480773	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by cellTiter-glo assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by cellTiter-glo assay	[PMID: 36708678]
MT4	CC₅₀	5.821 μM Compound: VRX-480773	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 4 days MTT method Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 4 days MTT method	[PMID: 26162497]
MT4	EC₅₀	0.00014 μM Compound: VRX-480773	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity incubated for 4 days by MTT method Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity incubated for 4 days by MTT method	[PMID: 26162497]
MT4	EC₅₀	0.00023 μM Compound: VRX-480773	Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N + Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity incubated for 4 days by MTT method Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N + Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity incubated for 4 days by MTT method	[PMID: 26162497]
MT4	EC₅₀	0.14 μM Compound: VRX-480733	Antiviral activity against HIV1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay Antiviral activity against HIV1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay	[PMID: 23084898]
MT4	EC₅₀	0.14 μM Compound: VRX-480773	Antiviral activity against HIV1 3B in human MT4 cells assessed as protection of cell against virus-induced cytopathogenicity Antiviral activity against HIV1 3B in human MT4 cells assessed as protection of cell against virus-induced cytopathogenicity	[PMID: 18824350]
MT4	EC₅₀	0.14 μM Compound: VRX-480773	Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	[PMID: 21872971]
MT4	EC₅₀	0.14 μM Compound: VRX-480773	Antiviral activity against HIV-1 3B infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay Antiviral activity against HIV-1 3B infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay	[PMID: 22883027]
MT4	EC₅₀	0.23 μM Compound: VRX-480733	Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay	[PMID: 23084898]
MT4	EC₅₀	0.23 μM Compound: VRX-480773	Antiviral activity against HIV-1 3B harboring RT K103N and Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay Antiviral activity against HIV-1 3B harboring RT K103N and Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	[PMID: 21872971]
MT4	EC₅₀	0.23 μM Compound: VRX-480773	Antiviral activity against HIV-1 RES056 harboring RT K103N/Y181C mutant gene infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay Antiviral activity against HIV-1 RES056 harboring RT K103N/Y181C mutant gene infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay	[PMID: 22883027]

Chemical Information

CAS No. 878670-89-4
분자량 592.92
화학식 C₂₃H₁₉BrClN₅O₃S₂
SMILES

O=C(NC1=CC=C(S(=O)(N)=O)C=C1Cl)CSC2=NN=C(Br)N2C3=C4C=CC=CC4=C(C5CC5)C=C3
선적

Room temperature in continental US; may vary elsewhere.
보관

Please store the product under the recommended conditions in the Certificate of Analysis.

순도&문서

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (270 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Zhang Z, et al. A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2007 Feb;51(2):429-37. [Content Brief]

Calculators

몰농도 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

농도 희석 계산기

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

견적 받기 해외재고보유

Other size

견적 받기

Amount: USD 0.00

Biological Activity
- 제품 설명
- IC₅₀ & Target
Chemical Information
순도&문서
References

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

상품명:
CAS No.:
Species:
Purity:
수량:

VRX-480773

All HIV Isoforms

Biological Activity

제품 설명

IC50 & Target

Cellular Effect

Chemical Information

순도&문서

References

Calculators

Help & FAQs

VRX-480773 Related Classifications

HY-19869 Related Classifications

Bioz

Keywords

Your Recently Viewed Products

IC₅₀ & Target